We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?
Read MoreHide Full Article
T2 Biosystems, Inc. (TTOO - Free Report) is scheduled to release first-quarter 2020 results on May 5, after the opening bell. The company reported a negative earnings surprise of 11.1% in the last reported quarter.It has a trailing four-quarter negative earnings surprise of 8.5%, on average.
Q1 Estimates
The Zacks Consensus Estimate for first-quarter 2020 earnings is pegged at 28 cents per share, indicating an improvement of 17.7% from the year-ago reported figure.
Factors to Note
T2 Biosystems’ first-quarter produce revenues are likely to reflect growing test panel instrument sales. This, in turn, might have contributed to the company’s performance in the to-be-reported quarter.
Per the preliminary announcement, first-quarter 2020 total revenues are expected to range between $2.2 million and $2.6 million. Product revenues are estimated in the range of $0.9-$1.1 million.
Further, research and grant contribution revenues are anticipated in the band of $1.3-$1.5 million.
In March, T2 Biosystems — the only company with solutions to detect sepsis causing pathogens — received a multiyear Innovative Technology contract from Vizient, Inc.
Further, in the same month, the company announced a worldwide licensing agreement of COVID-19, novel coronavirus assayfrom Hackensack Meridian Health’s Center for Discovery and Innovation. The assay will be adapted to run on T2 Biosystems’ FDA-cleared T2Dx Instrument.
These developments are likely to have positively impacted the company’s first-quarter performance.
In 2020, the company has been focused on advancing programs funded by the $69 million milestone-based government contract awarded in September 2019. This includes the next generation instrument and expanded panel, and a novel biothreat panel. This, in turn, is likely to reflect on the company’s first-quarter performance.
Earnings Whispers
Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see below.
Earnings ESP: T2 Biosystems has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Haemonetics Corporation (HAE - Free Report) has an Earnings ESP of +2.76% and a Zacks Rank of 3.
Aurora Cannabis Inc. (ACB - Free Report) has an Earnings ESP of +9.09% and a Zacks Rank of 3.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?
T2 Biosystems, Inc. (TTOO - Free Report) is scheduled to release first-quarter 2020 results on May 5, after the opening bell. The company reported a negative earnings surprise of 11.1% in the last reported quarter.It has a trailing four-quarter negative earnings surprise of 8.5%, on average.
Q1 Estimates
The Zacks Consensus Estimate for first-quarter 2020 earnings is pegged at 28 cents per share, indicating an improvement of 17.7% from the year-ago reported figure.
Factors to Note
T2 Biosystems’ first-quarter produce revenues are likely to reflect growing test panel instrument sales. This, in turn, might have contributed to the company’s performance in the to-be-reported quarter.
Per the preliminary announcement, first-quarter 2020 total revenues are expected to range between $2.2 million and $2.6 million. Product revenues are estimated in the range of $0.9-$1.1 million.
Further, research and grant contribution revenues are anticipated in the band of $1.3-$1.5 million.
T2 Biosystems, Inc. Price and EPS Surprise
T2 Biosystems, Inc. price-eps-surprise | T2 Biosystems, Inc. Quote
In March, T2 Biosystems — the only company with solutions to detect sepsis causing pathogens — received a multiyear Innovative Technology contract from Vizient, Inc.
Further, in the same month, the company announced a worldwide licensing agreement of COVID-19, novel coronavirus assayfrom Hackensack Meridian Health’s Center for Discovery and Innovation. The assay will be adapted to run on T2 Biosystems’ FDA-cleared T2Dx Instrument.
These developments are likely to have positively impacted the company’s first-quarter performance.
In 2020, the company has been focused on advancing programs funded by the $69 million milestone-based government contract awarded in September 2019. This includes the next generation instrument and expanded panel, and a novel biothreat panel. This, in turn, is likely to reflect on the company’s first-quarter performance.
Earnings Whispers
Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see below.
Earnings ESP: T2 Biosystems has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Luminex Corporation has an Earnings ESP of +14.28% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics Corporation (HAE - Free Report) has an Earnings ESP of +2.76% and a Zacks Rank of 3.
Aurora Cannabis Inc. (ACB - Free Report) has an Earnings ESP of +9.09% and a Zacks Rank of 3.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>